NCT02895360 - Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2016

Primary Completion Date

August 7, 2020

Study Completion Date

August 7, 2020

Conditions

Neoplasms

Interventions

DRUG

BAL101553

BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2 (study days 15-21)

DRUG

BAL101553 at MTD

BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; treatment with maximum tolerated dose (MTD)

Trial Locations (6)

Centre Hospitalier Universitaire Vaudois, Lausanne

Inselspital Bern, Bern

Oncology Institute of Southern Switzerland; Ospedale Regionale San Giovanni Bellinzona e Valli, Bellinzona

Cantonal Hospital of Grisons, Department of Oncology/ Haematology, Chur

UniversitaetsSpital Zürich, Zurich

Cantonal Hospital of St. Gallen, Dep. Medical Oncology & Hematology, Sankt Gallen